Us Congress 2023-2024 Regular Session

Us Congress Senate Bill SB5056

Introduced
9/16/24  

Caption

SIMSA Act of 2024 Stop the Importation and Manufacturing of Synthetic Analogues Act of 2024

Impact

The introduction of Schedule A will affect the regulation of various drugs and substances, establishing compatibility with international treaties, and enhancing public safety. The bill requires that any substance in this category be appropriately registered with the Attorney General, who will determine if the registration is in the public interest. By doing so, the bill seeks to manage and reduce the potential for abuse of substances which may currently fall into regulatory gray areas.

Summary

SB5056, also known as the Stop the Importation and Manufacturing of Synthetic Analogues Act of 2024, aims to amend the Controlled Substances Act to introduce a new category of controlled substances known as Schedule A. This category is designated for substances that have a chemical structure similar to existing controlled substances and that manifest similar stimulant, depressant, or hallucinogenic effects on the central nervous system. The bill addresses the regulatory challenges posed by synthetic analogues which have become increasingly prevalent in illicit drug markets.

Conclusion

Overall, SB5056 represents a proactive approach to modernize the framework of the Controlled Substances Act to address emerging challenges associated with synthetic drugs. It reflects an intent to balance the necessity for regulation with the implications for researchers and medical providers who may utilize substances in this new category.

Contention

There are significant points of contention surrounding the bill, particularly concerning the rigorous penalties outlined for violations involving Schedule A substances. The act specifies severe penalties for offenses, including potential prison terms of up to 20 years for importing or exporting these substances without proper labeling or registration, which has raised concerns among some advocacy groups about the impact on research and medical uses. Additionally, researchers who were previously working with substances classified under Schedule A may face complications in maintaining compliance, resulting in a chilling effect on scientific inquiry and development.

Companion Bills

US HB9879

Same As SIMSA Act of 2024 Stop the Importation and Manufacturing of Synthetic Analogues Act of 2024

Similar Bills

US HB27

Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl ActThis bill permanently places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.Under the bill, offenses involving fentanyl-related substances are triggered by the same quantity thresholds and subject to the same penalties as offenses involving fentanyl analogues (e.g., offenses involving 100 grams or more trigger a 10-year mandatory minimum prison term).Additionally, the bill establishes a new, alternative registration process for certain schedule I research.The bill also makes several other changes to registration requirements for conducting research with controlled substances, includingpermitting a single registration for related research sites in certain circumstances,waiving the requirement for a new inspection in certain situations, andallowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration.Finally, the bill expresses the sense that Congress agrees with the interpretation of Controlled Substances Act in United States v. McCray, a 2018 case decided by the U.S. District Court for the Western District of New York. In that case, the court held that butyryl fentanyl, a controlled substance, can be considered an analogue of fentanyl even though, under the Controlled Substances Act, the term controlled substance analogue specifically excludes a controlled substance.

US SB331

HALT Fentanyl Act Halt All Lethal Trafficking of Fentanyl Act

US SB4187

Forever Chemical Regulation and Accountability Act of 2024

US SB3006

SAFE in Recovery Act Substance Use Disorder and Family Engagement in Recovery Act

US SB767

HIDTA Enhancement Act

US SB3393

SUPPORT for Patients and Communities Reauthorization Act

US HB2964

Fight Fentanyl Act

US HB1100

STOPP Act Stop the Opioid Pill Presser and Fentanyl Act